Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer:effects on long-term survival and combined therapy with next-generation hormonal agents  

作　　者：Jinge Zhao Junru Chen Guangxi Sun Pengfei Shen Hao Zeng 

机构地区：[1]Department of Urology,Institute of Urology,West China Hospital,Sichuan University,Chengdu 610041,China

出　　处：《Cancer Biology & Medicine》2024年第11期1012-1032,共21页癌症生物学与医学(英文版)

摘　　要：Prostate cancer is a leading cause of cancer-related death in men worldwide.Luteinizing hormone-releasing hormone receptor(LHRH-R)agonists and antagonists are known to achieve castration-level testosterone suppression;however,long-term data comparing the survival benefits of these therapies are insufficient to inform treatment decisions.Furthermore,the advent of nextgeneration hormonal agents(NHAs),such as abiraterone and enzalutamide,have shifted the paradigm of managing prostate cancer.Although LHRH-R agonists and antagonists remain the cornerstone treatment across various stages of prostate cancer,they are increasingly administered with NHAs,because the combination treatment confers a survival advantage.Nevertheless,the differences in efficacy and safety profiles among various combinations of LHRH-R agonists and antagonists and NHAs remain unclear.Hence,this narrative review is aimed at providing a comprehensive overview of the long-term outcomes of various LHRH-R agonists and antagonists.Key data from major clinical studies are summarized,categorized by disease stage.LHRH-R agonists and antagonists,particularly goserelin,have demonstrated long-term survival benefits in patients with localized and locally advanced prostate cancer.The clinical outcomes of different LHRH-R agonists and antagonists in combination with NHAs have also been evaluated.Among the various combinations,goserelin plus abiraterone appears to have a manageable safety profile with relatively low rates of hot flushes and fatigue.Overall,long-term survival data and safety profiles should be considered in selecting optimal combination therapies for prostate cancer treatment.

关 键 词：Luteinizing hormone-releasing hormone receptor agonists luteinizing hormone-releasing hormone receptor antagonists prostate cancer long-term survival next-generation hormonal agents 

分 类 号：R737.25[医药卫生—肿瘤]